<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00116558</url>
  </required_header>
  <id_info>
    <org_study_id>R01NS045087</org_study_id>
    <secondary_id>R01NS045087</secondary_id>
    <nct_id>NCT00116558</nct_id>
  </id_info>
  <brief_title>Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation</brief_title>
  <official_title>Early Treatment of Amyotrophic Lateral Sclerosis With Nutrition and Non-Invasive Positive Pressure Ventilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edward Kasaraskis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of the study are to determine the energy balance and evaluate the nutritional
      status of patients with ALS, and to investigate the use of NIPPV as respiratory support to
      treat patients with ALS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies to date indicate that percutaneous endoscopic gastrostomy (PEG)—insertion of a
      feeding tube in the stomach—and non-invasive positive pressure ventilation
      (NIPPV)—mechanically assisted or generated breaths delivered through a tightly fitting nasal
      or facial mask—improve survival in amyotrophic lateral sclerosis (ALS), even when introduced
      late in the disease.

      Dr. Kasarskis and his research team believe early intervention with these treatments may
      improve patients outcome even further. However, many issues regarding the early use of these
      treatments prevent the design of a phase III clinical trial to test this hypothesis. Common
      to both NIPPV and nutrition is a lack of a reliable indicator of early respiratory or
      nutritional insufficiency. With respect to nutrition, reliable and cost effective methods are
      needed to determine a patient's energy (i.e. caloric) requirements at different stages of the
      illness to establish a basis for recommending PEG on the adequacy of energy intake. For
      NIPPV, factors that influence acceptance and tolerability of this therapy, and measurements
      of early respiratory dysfunction need to be identified.

      The purposes of this trial are to develop and validate strategies to improve tolerability of
      NIPPV, identify factors that influence acceptance of NIPPV, and evaluate measures of early
      respiratory failure, other than percentage of forced vital capacity (FVC). Researchers will
      also develop and validate methods to determine energy balance in and evaluate the nutritional
      status of patients with ALS that will be applicable to a multi-center phase III study of
      nutrition and NIPPV.

      The study will be conducted at 11 other sites across the country. Some study sites will focus
      on the nutritional aspects of the trial while the other sites will focus on NIPPV treatment.
      A total of 220 patients will be studied over 2 years.

      Enrollment will end on June 30, 2007. The last patient was followed clinically until June 30,
      2008. The study remained open for sample analysis, data analysis, and assessment of vital
      status until the completion of funding on November 30, 2009.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2004</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment.</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage of patients attempting to use NIPPV therapy within six weeks of initial offer.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Patient Survival With Early Versus Standard of Care NIPPV Treatment</measure>
    <time_frame>one year</time_frame>
    <description>Duration of patient survival</description>
  </other_outcome>
  <other_outcome>
    <measure>Compliance With NIPPV Treatment</measure>
    <time_frame>one month</time_frame>
    <description>Number of hours of NIPPV use per month</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Daily Energy Expediture (TDEE) of ALS Patients</measure>
    <time_frame>Duration of study (approximately 1 year)</time_frame>
    <description>Total daily energy expenditure (TDEE) with be measured using the dual labeled water (DLW) method</description>
  </other_outcome>
  <other_outcome>
    <measure>Tolerance of NIPPV Treatment</measure>
    <time_frame>one month</time_frame>
    <description>Percent of patients achieving tolerance (&gt;4hr/night NIPPV after 2-3 week titration period) determined by actual usage data.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Early NIPPV Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with &gt;80% predicted forced vital capacity (FVC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care NIPPV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with 50-74% predicted forced vital capacity (FVC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care NIPPV and Nutritional Monitoring</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with 50-95% forced vital capacity (FVC), and normal or impaired amyotrophic lateral sclerosis functional rating scale (ALSFRS) scores. Participants in this group will receive standard of care NIPPV therapy but will also undergo detailed analysis of nutritional status.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Early NIPPV</intervention_name>
    <description>Early intervention with non-invasive positive pressure ventilation (NIPPV) at 80% forced vital capacity (FVC).</description>
    <arm_group_label>Early NIPPV Intervention</arm_group_label>
    <other_name>BiPAP (Bilevel Positive Airway Pressure)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard NIPPV</intervention_name>
    <description>Standard of care non-invasive positive pressure ventilation (NIPPV) at 50% forced vital capacity (FVC).</description>
    <arm_group_label>Standard of Care NIPPV</arm_group_label>
    <arm_group_label>Standard of Care NIPPV and Nutritional Monitoring</arm_group_label>
    <other_name>BiPAP (Bilevel Positive Airway Pressure)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to give informed consent.

          -  If women of childbearing age, must be non-lactating and surgically sterile or using an
             effective method of birth control (double-barrier or oral contraception) and have a
             negative pregnancy test.

          -  Minorities: All races and ethnic backgrounds.

          -  Disease inclusion: Clinically possible/definite/probable, or laboratory supported
             probable, sporadic or familial ALS according to the revised Escorial criteria.

          -  Onset of progressive weakness within 60 months prior to study.

          -  Willing to return for visits as scheduled and adhere to protocol requirements.

        FVC Criteria

          -  NIPPV Arm: Best-sitting FVC between 50% and 95% of predicted normal.

          -  Nutrition Arm: Best-sitting FVC &gt;50% of predicted normal.

        Exclusion Criteria:

          -  Untreated or unstable hyper or hypothyroidism, untreated or unstable asthma, unstable
             angina, advanced liver or renal disease, advanced cancer, untreated diabetes or
             chronic obstructive pulmonary disease (COPD).

          -  Diagnosis of other motor neuron or other neurological disorder that mimics ALS.

          -  Diagnosis of other neurodegenerative disease (i.e., Parkinson's disease, Alzheimer's
             disease, etc.)

          -  Inflammatory bowel disease or malabsorption syndrome.

          -  Use of NIPPV, mechanical ventilation, or tracheostomy at the time of consent.

          -  Inability to adhere to study visit schedule or lack of reliable caretaker if
             participant requires one.

          -  Pregnant or lactating woman.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Kasarskis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania State University</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas-San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>54505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kasarskis EJ, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, Bromberg MB, Kryscio RJ; ALS Nutrition/NIPPV Study Group. Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis. Am J Clin Nutr. 2014 Apr;99(4):792-803. doi: 10.3945/ajcn.113.069997. Epub 2014 Feb 12.</citation>
    <PMID>24522445</PMID>
  </reference>
  <reference>
    <citation>Scagnelli CN, Howard DB, Bromberg MB, Kasarskis EJ, Matthews DE, Mitsumoto HM, Simmons Z, Tandan R; ALS Nutrition-NIPPV Study Group. Hydration measured by doubly labeled water in ALS and its effects on survival. Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):220-231. doi: 10.1080/21678421.2017.1413117. Epub 2017 Dec 15.</citation>
    <PMID>29243507</PMID>
  </reference>
  <results_reference>
    <citation>Kasarskis EJ, Mendiondo MS, Wells S, Malguizo MS, Thompson M, Healey M, Kryscio RJ; ALS Nutrition/NIPPV Study Group. The ALS Nutrition/NIPPV Study: design, feasibility, and initial results. Amyotroph Lateral Scler. 2011 Jan;12(1):17-25. doi: 10.3109/17482968.2010.515225.</citation>
    <PMID>21271789</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 29, 2005</study_first_submitted>
  <study_first_submitted_qc>June 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2005</study_first_posted>
  <results_first_submitted>March 15, 2010</results_first_submitted>
  <results_first_submitted_qc>July 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2019</results_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Edward Kasaraskis</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>amyotrophic lateral sclerosis</keyword>
  <keyword>ALS</keyword>
  <keyword>Lou Gehrig's disease</keyword>
  <keyword>nutrition</keyword>
  <keyword>NIPPV</keyword>
  <keyword>non-invasive positive pressure ventilation</keyword>
  <keyword>percutaneous endoscopic gastrostomy</keyword>
  <keyword>PEG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard of Care NIPPV and Nutritional Monitoring</title>
          <description>Participants with 50-95% forced vital capacity (FVC), and normal or impaired amyotrophic lateral sclerosis functional rating scale (ALSFRS) scores. Participants in this group will receive standard of care NIPPV therapy but will also undergo detailed analysis of nutritional status.</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care NIPPV</title>
          <description>Participants with 50-74% predicted forced vital capacity (FVC).</description>
        </group>
        <group group_id="P3">
          <title>Early NIPPV</title>
          <description>Participants with &gt;80% predicted forced vital capacity (FVC).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>disease progression</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard of Care NIPPV and Nutritional Monitoring</title>
          <description>Participants with 50-95% forced vital capacity (FVC), and normal or impaired amyotrophic lateral sclerosis functional rating scale (ALSFRS) scores. Participants in this group will receive standard of care NIPPV therapy but will also undergo detailed analysis of nutritional status.</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care NIPPV</title>
          <description>Participants with 50-74% predicted forced vital capacity (FVC).</description>
        </group>
        <group group_id="B3">
          <title>Early NIPPV Intervention</title>
          <description>Participants with &gt;80% predicted forced vital capacity (FVC).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="47"/>
            <count group_id="B4" value="153"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.0" spread="11.7"/>
                    <measurement group_id="B2" value="60.8" spread="11.4"/>
                    <measurement group_id="B3" value="56.2" spread="11.2"/>
                    <measurement group_id="B4" value="58.6" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment.</title>
        <description>Percentage of patients attempting to use NIPPV therapy within six weeks of initial offer.</description>
        <time_frame>6 weeks</time_frame>
        <population>Data were not obtained from the &quot;Standard of Care NIPPV and Nutritional Monitoring&quot; arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care NIPPV and Nutritional Monitoring</title>
            <description>Participants with 50-95% forced vital capacity (FVC), and normal or impaired amyotrophic lateral sclerosis functional rating scale (ALSFRS) scores. Participants in this group will receive standard of care NIPPV therapy but will also undergo detailed analysis of nutritional status.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care NIPPV</title>
            <description>Participants with 50-74% predicted forced vital capacity (FVC).</description>
          </group>
          <group group_id="O3">
            <title>Early NIPPV Intervention</title>
            <description>Participants with &gt;80% predicted forced vital capacity (FVC).</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment.</title>
          <description>Percentage of patients attempting to use NIPPV therapy within six weeks of initial offer.</description>
          <population>Data were not obtained from the &quot;Standard of Care NIPPV and Nutritional Monitoring&quot; arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Survival With Early Versus Standard of Care NIPPV Treatment</title>
        <description>Duration of patient survival</description>
        <time_frame>one year</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compliance With NIPPV Treatment</title>
        <description>Number of hours of NIPPV use per month</description>
        <time_frame>one month</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Total Daily Energy Expediture (TDEE) of ALS Patients</title>
        <description>Total daily energy expenditure (TDEE) with be measured using the dual labeled water (DLW) method</description>
        <time_frame>Duration of study (approximately 1 year)</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Tolerance of NIPPV Treatment</title>
        <description>Percent of patients achieving tolerance (&gt;4hr/night NIPPV after 2-3 week titration period) determined by actual usage data.</description>
        <time_frame>one month</time_frame>
        <population>No data were collected for the &quot;Standard of Care NIIPPV and Nutritional Monitoring&quot; arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care NIPPV and Nutritional Monitoring</title>
            <description>Participants with 50-95% forced vital capacity (FVC), and normal or impaired amyotrophic lateral sclerosis functional rating scale (ALSFRS) scores. Participants in this group will receive standard of care NIPPV therapy but will also undergo detailed analysis of nutritional status.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care NIPPV</title>
            <description>Participants with 50-74% predicted forced vital capacity (FVC).</description>
          </group>
          <group group_id="O3">
            <title>Early NIPPV</title>
            <description>Participants with &gt;80% predicted forced vital capacity (FVC).</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerance of NIPPV Treatment</title>
          <description>Percent of patients achieving tolerance (&gt;4hr/night NIPPV after 2-3 week titration period) determined by actual usage data.</description>
          <population>No data were collected for the &quot;Standard of Care NIIPPV and Nutritional Monitoring&quot; arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years, 4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Combined Arms</title>
          <description>Sincere efforts were made to locate per arm data, but these data are no longer available. All adverse events are reported as one arm/group.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <description>Dates: 4/4/2006 4/4/2006 Status: Resolved Reason for Qualifying: Resulting in death Intensity: Severe Relationship to Study: Unrelated Description: Cardiac Arrest</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Irregular Heartbeat</sub_title>
                <description>Dates: 1/18/2008 2/17/2008 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to study: Unrelated Description: Irregular Heartbeat</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <description>Dates: 8/30/2007 8/31/2007 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to study: Unrelated Description: Apparent Myocardial Infarction</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic Bleed</sub_title>
                <description>Dates: 1/15/2007 1/29/2007 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship: Unrelated Description: Left Colonic Bleed</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dislodged PEG Tube</sub_title>
                <description>Dates: 6/30/2007 Status: Continuing at discontinuation Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to Study: Unrelated Description: Dislodged PEG Tube and Respiratory Distress</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Distended Abdomen</sub_title>
                <description>Dates: 8/24/2005 8/29/2005 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Moderate Relationship to Study: Unrelated Description: Distended Abdomen</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <description>Dates: 3/11/2008 3/11/2008 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to study: Unrelated Description: Dysphagia</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>PEG Procedure Complications</sub_title>
                <description>Dates: 5/11/2006 5/12/2006 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Moderate Relationship to study: Unrelated Description: Complications from PEG Procedure</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Dates: 10/3/2007 10/11/2007 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to Study: Unrelated Description: Severe Sepsis around PEG Tube</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Dates: 6/2/2006 6/2/2006 Status: Resolved Reason for Qualifying: Resulting in death Intensity: Severe Relationship to Study: Unrelated Description: No Information Given</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Dates: 10/3/2007 10/11/2007 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to study: Unrelated Description: Severe infection</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to Thrive</sub_title>
                <description>Dates: 7/23/2007 8/10/2007 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Moderate Relationship to Study: Unrelated Description: Diagnosed as failure to thrive</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hypokalemia, hypomagnesia, and antythmia</sub_title>
                <description>Dates: 12/15/2007 12/17/2007 Status: Resolved Reason for qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to study: Unrelated Description: Hypokalemia, hypomagnesia, and antythmia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <description>Dates: 4/25/2006 5/4/2006 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Moderate Relationship to study: Unrelated Description: Left Hip Fracture Resulting From Fall</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Liver Cancer Diagnosis</sub_title>
                <description>Dates: 11/4/2005 Status: Continuing at discontinuation Reason for Qualifying: Are other conditions which represent significant hazards Intensity: Severe Relationship to Study: Unrelated Description: Liver Cancer Diagnosis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Transitional Cell Carcinoma</sub_title>
                <description>Dates: 9/6/2007 9/23/2007 Status: Resolved Reason for Qualifying: Resulting in death Intensity: Severe Relationship to study: Unrelated Description Small bowel obstruction, transitional cell carcinoma</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ALS Progression</sub_title>
                <description>Dates: 5/5/2007 5/25/2007 Status: Resolved Reason for Qualifying: Are other conditions which represent significant hazards Intensity: Moderate Relationship to study: Unrelated Description: Treatment and Evaluation of ALS Progression</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <description>Dates: 2/7/2007 2/7/2007 Status: Resolved Reason for Qualifying: Life-threatening Intensity: Moderate Relationship to Study: Unrelated Description: Concussion as result of Automobile Accident</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder malignancy/UTI</sub_title>
                <description>Dates: 8/22/2007 9/5/2007 Status: Resolved Reason for qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to Study: Unrelated Description: Possible bladder malignancy and UTI</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <description>Dates: 5/11/2008 5/12/2008 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Mild Relationship to study: Unrelated Description: Aspiration</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Aspiration Pneumonia</sub_title>
                <description>Dates: 6/10/2007 6/19/2007 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Moderate Relationship to Study: Unrelated Description: Presumed Aspiration Pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Blood Clot</sub_title>
                <description>Dates: 8/21/2005 9/1/2005 Status:Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Moderate Relationship to study: Unrelated Description: Blood Clot Behind right knee</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Difficulty Breathing</sub_title>
                <description>Dates: 5/21/2007 5/27/2007 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Moderate Relationship to Study: Unrelated Description: Difficulty breathing due to Sialorrhea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Dates: 4/9/2007 Status: Continuing at discontinuation Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to study: Unrelated Description: Increased Dyspnea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Loculated right pleural effusion</sub_title>
                <description>Dates: 7/27/2007 8/2/2007 Status: Resolved Reason for qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to Study: Unrelated Description: Loculated right pleural effusion and possible Pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Dates: 3/6/2008 3/19/2008 Status: Resolved Reason for qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to study: Unrelated Description: Pneumonia</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pulmonary Emboli and pneumonia</sub_title>
                <description>Dates: 9/3/2006 10/5/2006 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to study: Unrelated Description: Pulmonary emboli and pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Respiratory Complications</sub_title>
                <description>Dates: 10/7/2006 10/7/2006 Status: Resolved Reason for Qualifying: Resulting in death Intensity: Severe Relationship to study: Unrelated Description: Respiratory Complications</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <description>Dates: 9/28/2007 9/28/2007 Status: Resolved Reason for qualifying: Requiring or prolonging Hospitalization Intensity: Severe Relationship to study: Unrelated Description: continued respiratory decline</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <description>Dates: 10/2/2006 Status: Continuing at discontinuation Reason for Qualifying: Are other conditions which represent significant hazards Intensity: Severe Relationship: Unrelated Description: Shortness of breath</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <description>Dates: 9/9/2007 11/4/2007 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to Study: Unrelated Description: Debridement and Closure of Laceration</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Subarachroid Hemmorrhage and Contusion</sub_title>
                <description>Dates: 3/14/2007 3/16/2007 Status: Resolved Reason for Qualifying: Resulting in death Severe Relationship to Study: Unrelated Description: Sub-arachnoid Haemmorrhage and Contusion Resulting from fall</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Subdural Hematoma</sub_title>
                <description>Dates: 6/11/2007 6/11/2007 Status: Resolved Reason for Qualifying: Requiring or prolonging hospitalization Intensity: Severe Relationship to Study: Unrelated Description: Subdural Hematoma from fall</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Peg Replacement</sub_title>
                <description>Dates: 3/14/2008 3/18/2008 Status: Resolved Reason for qualifying: Requiring or prolonging hospitalization Intensity: Mild Relationship to study: Unrelated Description: PEG replacement</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <description>Dates: 10/24/2006 Status: Unresolved at 48 Weeks Description: Edema Intensity: mild Relationship to study: not likely</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Dates: 1/11/2008 Status: Unresolved at 48 Weeks Description: Hypertension Intensity: mild Relationship to study: not likely</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Dates: 11/4/2006 11/4/2006 Status: Ended Description: Hypotension Intensity: mild Relationship to Study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Eye</sub_title>
                <description>Dates: 10/15/2007 Description:Dry Eye Intensity: mild Relationship to study: probable</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <description>Dates: 3/20/2007 Status: Unresolved at 48 Weeks Description: Abdominal distension Intensity: moderate Relationship to study: possible</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Dates: 2/1/2006 6/1/2006 Status: Resolved Description: Constipation Intensity: moderate Relationship to study: not likely</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Decreased Rectal Tone</sub_title>
                <description>Dates: 6/4/2007 Status: Continuing Description: Decreased Rectal Tone Intensity: moderate Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Dates: 3/5/2008 Description: Dehydration Intensity: mild Relationship to study: not likely</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dental</sub_title>
                <description>Dates: 4/17/2006 Status: Ended Description: Dental Intensity: moderate Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Dates: 2/10/2007 2/10/2007 Status: Ended Description: Diarrhea Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <description>Dates: 10/15/2006 11/14/2006 Status: Resolved Description: Diverticulitis Intensity: severe Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <description>Dates: 6/15/2006 Status: Unresolved at 48 Weeks Description: Dysphagia Intensity: mild Relationship to study: not likely</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <description>Dates: 9/25/2006 10/2/2006 Status: Ended Description: Gastritis Intensity: severe Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>PEG</sub_title>
                <description>Dates: 6/29/2006 7/1/2006 Status: Ended Description: PEG Intensity: moderate Relationship to study: not related</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sialorrhea</sub_title>
                <description>Dates: 2/10/2006 Status: Unresolved at 48 Weeks Description: Sialorrhea Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Stomach Upset</sub_title>
                <description>Dates: 4/29/2006 5/1/2006 Status: Ended Description: Stomach Upset Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Urgent Bowel Movements</sub_title>
                <description>Dates: 2/1/2006 Status: Unresolved at Discontinuation Description: Urgent Bowel Movements Intensity: mild Relationship to study: possible</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Dates: 10/18/2005 10/18/2005 Status: Ended Description: Vomiting Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Burning Sensation</sub_title>
                <description>Dates: 7/23/2007 Status: Continuing Description: PAIN Burning Sensation Intensity: severe Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cold</sub_title>
                <description>Dates: 8/9/2007 8/15/2007 Status: Ended Description: Cold Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <description>Dates: 4/13/2007 4/13/2007 Status: Ended Description: Fall Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Dates: 11/1/2005 Status: Unresolved at Discontinuation Description: Fatigue Intensity: severe Relationship to study: not related</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Dates: 11/20/2006 12/18/2006 Status: Resolved Description: Pain Intensity: moderate Relationship to study: not related</description>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <description>Dates: 10/12/2006 Status: Unresolved at 48 Weeks Description: Sore Throat Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <description>Dates: 8/8/2005 3/13/2006 Status: Ended Description: Weight Loss Intensity: moderate Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy</sub_title>
                <description>Dates: 4/17/2007 4/22/2007 Status: Ended Description: Allergy Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Congestion</sub_title>
                <description>Dates: 7/21/2006 7/31/2006 Status: Resolved Description: Congestion Intensity: moderate Relationship to study: not related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Post Nasal Drip</sub_title>
                <description>Dates: 3/31/2006 Status: Unresolved at 48 Weeks Description: Post Nasal Drip Intensity: severe Relationship to study: not related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <description>Dates: 7/3/2007 7/8/2007 Status: Ended Description: Conjunctivitis Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <description>Dates: 10/1/2006 10/26/2006 Status: Resolved Description: Ear Infection Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>Dates: 10/26/2007 11/4/2007 Status: Ended Description: Infection Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <description>Dates: 4/1/2007 4/7/2007 Status: Ended Description: Sinus Infection Severity: moderate Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>UTI</sub_title>
                <description>Dates: 3/14/2006 3/24/2006 Status: Ended Description: UTI Intensity: moderate Relationship to study: not related</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Lab</sub_title>
                <description>Dates: 5/2/2006 8/21/2006 Status: Resolved Description: Abnormal Lab Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hypercarbia</sub_title>
                <description>Dates: 11/6/2006 Status: Continuing Description: Hypercarbia Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle Sprain</sub_title>
                <description>Dates: 9/6/2006 Status: Ended Description: Ankle Sprain Intensity: moderate Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <description>Dates: 3/27/2007 Status: Unresolved at 48 Weeks Description: Arthritis Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <description>Dates:: 6/3/2006 Status: Unresolved at 48 weeks Description: Back Pain Intensity: moderate Relationship to study: not related</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <description>Dates: 1/18/2007 3/29/2007 Status: Resolved Description: Fracture Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Knee Sprain</sub_title>
                <description>Dates: 6/30/2007 7/13/2007 Status: Ended Description: Knee Sprain Intensity: moderate Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <description>Dates: 9/4/2006 Status: Unresolved at 48 Weeks Description: Osteopenia Intensity: mild Relationship to study: not likely</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Shoulder Pain</sub_title>
                <description>Dates: 1/23/2006 1/25/2006 Status: Ended Description: Shoulder Pain Intensity: severe Relationship to study: not related</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <description>Dates: 2/1/2006 Status: Unresolved at Discontinuation Description: Weakness Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon Polyp</sub_title>
                <description>Dates: 2/1/2006 2/1/2006 Status: Ended Description: Colon Polyp Intensity: mild Relationship: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <description>Dates: 2/6/2006 2/6/2006 Status: Ended Description: Concussion Intensity: severe Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Dates: 1/15/2006 Status: Ended Description: Dizziness Intensity: moderate Relationship to study: not related</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <description>Dates: 9/13/2006 9/16/2006 Status: Ended Description: Hallucination Intensity: moderate Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Dates: 1/18/2006 3/1/2006 Status: Ended Description: Headache Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Frequency</sub_title>
                <description>Dates: 6/11/2007 6/24/2007 Status: Ended Description: Urinary Frequency Intensity: moderate Relationship to study: not likely</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Clot</sub_title>
                <description>Dates: 1/28/2008 Status: Unresolved at 48 Weeks Description: Blood Clot Intensity: moderate Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>Dates: 1/20/2008 2/10/2008 Status: Ended Description: Bronchitis Intensity: moderate Relationship to study: possible</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Dates: 9/7/2006 Status: Ended Description: Cough Intensity: moderate Relationship: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Nosebleed</sub_title>
                <description>Dates: 11/1/2007 Status: Continuing Description: Nosebleed Intensity: mild Relationship to study: probable</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Dates: 11/1/2007 Status: Unresolved at 48 Weeks Description: Pneumonia Intensity: moderate Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>RADS</sub_title>
                <description>Dates: 1/17/2007 4/30/2007 Status: Ended Description: RADS Intensity: mild Relationship: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <description>Dates: 2/25/2007 2/25/2007 Status: Ended Description: Shortness of Breath Intensity: moderate Relationship to study: not related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Spasm (Respiratory)</sub_title>
                <description>Dates: 1/19/2007 1/19/2007 Status: Resolved Description: Spasm Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <description>Dates: 11/6/2006 Status: Resolved Description: Wheezing Intensity: moderate Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <description>Dates: 4/1/2008 Status: Unresolved at 48 Weeks Description: Blister Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Bruise</sub_title>
                <description>Dates: 5/11/2006 5/11/2006 Status:Ended Description: Bruise Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <description>Dates: 7/4/2007 7/4/2007 Status: Ended Description: Contusion Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <description>Dates: 3/1/2008 Status: Unresolved at 48 Weeks Description: Dermatitis Intensity: mild Relationship to study: possible</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <description>Dates: 2/5/2007 2/5/2007 Status: Ended Description: Laceration Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Lesion</sub_title>
                <description>Dates: 3/30/2007 5/7/2007 Status: Ended Description: Lesion Intensity: mild Relationship to study: definite</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pressure Sores</sub_title>
                <description>Dates: 11/28/2006 11/30/2006 Status: Resolved Description: Pressure Sores Intensity: mild Relationship to study: not related</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Dates: 8/15/2005 Status: Unresolved at 48 Weeks Description: Rash Intensity: mild Relationship to study: not likely</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Compliance with NIPPV intervention is limited due to technical difficulties in obtaining BiPAP download data from some sites. This was due to variability in the local respiratory therapists engaged by commercial respiratory therapy companies.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Edward J. Kasarskis, M.D., Ph.D.</name_or_title>
      <organization>University of Kentucky</organization>
      <phone>859-218-5061</phone>
      <email>ejkas@uky.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

